

REMARKS

Claims 1-23 are pending. Claims 24-25 have been cancelled. Claims 1, 9, and 16 have been amended based on recommendations made by the Examiner (Paper No. 13). The amended claims now require that administration be directly to a cutaneous site. Support for the amendments made to the claims is found on page 4, lines 24-29. Because the foregoing changes introduce no new matter, Applicants respectfully request their entry.

Claim Rejection – 35 USC §112, First Paragraph

Claims 1, 9 and 16 stand rejected under 35 USC §112, first paragraph, on the ground that the specification does not enable a person skilled in the art to make and use the claimed invention commensurate in scope with the claims.

Applicants have amended claims 1, 9, and 16, per Examiner's suggestion, to recite methods for modulating the inflammation, swelling, and infiltration of macrophage in a patient comprising administering *directly* to a cutaneous site in the patient, a recombinant nucleic acid comprising nucleic acid encoding a biologically active fragment of LIF and promoter which is operably linked thereto and capable of expressing LIF wherein the recombinant nucleic acid is expressed and the LIF is produced for modulating the inflammation, swelling, or infiltration of macrophage.

Applicants accordingly request withdrawal of the outstanding rejection.


CONCLUSION

Applicants submit that the claims are now in condition for allowance and early notification to that effect is respectfully requested. If the Examiner feels there are further unresolved issues, the Examiner is respectfully requested to phone the undersigned at (415) 781-1989.

Respectfully submitted,

DORSEY & WHITNEY LLP

Dated: 9/30/03



Richard F. Trecartin, Reg. No. 31,801
Filed under 37 C.F.R. § 1.34(a)

Four Embarcadero Center, Suite 3400
San Francisco, California 94111
Telephone: (415) 781-1989
1120063